Aspen Pharmacare Holdings Limited (APNHF)
OTHER OTC:APNHF
Earnings Data
Report Date
Sep 02, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.42Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic outlook: commercial pharmaceutical operations are performing well with solid revenue and margin expansion, GLP-1 products are delivering rapid market momentum, and the group has materially improved cash generation. Major near-term headwinds stem from a significant manufacturing contract loss and continuing sterile business losses, which depressed H1 EBITDA and HEPS. The planned APAC divestment (expected net proceeds >ZAR 25 billion) and ongoing cost and reshaping actions are positioned to materially reduce debt, unlock value, and fund a recovery—management expects a much stronger second half and recovery to FY27 levels. Overall, positives (strong cash flow, commercial pharma/GLP-1 growth, APAC monetization) outweigh the near-term negatives (manufacturing/steriles impact and H1 earnings decline), supporting a constructive outlook.Company Guidance
Commercial Pharma Revenue and EBITDA Growth
Commercial pharma revenue grew ~4% in constant exchange rate (CER) and CER EBITDA grew ~11%; commercial pharma EBITDA margin expanded from 28.3% to 29.2% with gross margin stable at ~58.5%—demonstrating strong core operating performance.
GLP-1 (Mounjaro & Semaglutide) Momentum
GLP-1 market in South Africa tripled to ~ZAR 2.2 billion in 18 months; Mounjaro market share rose from 21% to 52%; company expects Mounjaro sales in South Africa of at least ~ZAR 1.3 billion in the period and registration/rollout into Sub-Saharan Africa to begin in the 2026–2027 period. Semaglutide generic opportunity targeted for early entrants (calendar Q2 potential in Canada).
Free Cash Flow and Cash Generation
Generated ~ZAR 3.6 billion cash from operations (H1) vs ZAR 1.8 billion prior comparable half; CapEx reduced from ~ZAR 2.6 billion to ~ZAR 1.6 billion; produced just under ZAR 2 billion of free cash flow for the half.
Debt Reduction and Balance Sheet Flexibility
Net debt reduced to ZAR 28.6 billion from ZAR 31.2 billion (June 2025); leverage ~3.4x. Management expects APAC sale proceeds to largely eliminate net debt on completion, materially improving balance sheet flexibility.
APAC Divestment Value and Expected Proceeds
APAC divestment gross consideration AUD 237 million (previously guided ~ZAR 26.5 billion at AUD/ZAR ~11.05); net proceeds expected >ZAR 25 billion; assets held for sale net book value ~ZAR 21.8 billion; expected profit on sale ~ZAR 1.8–2.0 billion to be reported in H2 and sizable interest savings reducing group interest expense.
Positive H2 and FY Guidance
Management guides to a much stronger second half: double-digit normalized HEPS growth for the full year, EBITDA in H2 at least double H1 continuing-operations EBITDA, commercial pharma mid-single digit revenue growth and double-digit CER EBITDA growth, and manufacturing expected to be in line with prior year.
Operational Reshaping and Contract Outcomes
~90% of the group reshaping complete; contract dispute closed; expected annualized savings and contract commercialization (insulin ramp-up) to contribute to recovery and improved margins (steriles targeted to achieve breakeven/positive EBITDA by FY27).
ESG and Access Progress
Volumes of critical medicines increased ~8% vs FY24; top leadership female representation rose to 32% (from 19% in FY20); Scope 1 & 2 emissions reduced ~24% vs FY20; renewable energy usage ~19% with solar at eight manufacturing sites.
APNHF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APNHF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $8.37 | $8.27 | -1.20% |
Sep 03, 2025 | $5.72 | $5.64 | -1.38% |
Mar 03, 2025 | $11.98 | $11.98 | 0.00% |
Oct 02, 2024 | $11.98 | $11.98 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aspen Pharmacare Holdings Limited (APNHF) report earnings?
Aspen Pharmacare Holdings Limited (APNHF) is schdueled to report earning on Sep 02, 2026, TBA (Confirmed).
What is Aspen Pharmacare Holdings Limited (APNHF) earnings time?
Aspen Pharmacare Holdings Limited (APNHF) earnings time is at Sep 02, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APNHF EPS forecast?
Currently, no data Available